Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma brucei | DNA topoisomerase IB, large subunit | 0.0161 | 0 | 0.5 |
Plasmodium falciparum | topoisomerase I | 0.0215 | 0.323 | 0.5 |
Brugia malayi | Serine/threonine-protein kinase Pim-3 | 0.0328 | 1 | 1 |
Schistosoma mansoni | serine/threonine protein kinase | 0.0328 | 1 | 1 |
Loa Loa (eye worm) | CAMK/PIM protein kinase | 0.0328 | 1 | 1 |
Plasmodium vivax | topoisomerase I, putative | 0.0215 | 0.323 | 0.5 |
Echinococcus granulosus | proto oncogene serine:threonine protein kinase | 0.0328 | 1 | 1 |
Echinococcus multilocularis | proto oncogene serine:threonine protein kinase | 0.0328 | 1 | 1 |
Loa Loa (eye worm) | CAMK/PIM protein kinase | 0.0328 | 1 | 1 |
Leishmania major | DNA topoisomerase IB, large subunit | 0.0161 | 0 | 0.5 |
Schistosoma mansoni | DNA topoisomerase type I | 0.0215 | 0.323 | 0.323 |
Trypanosoma cruzi | DNA topoisomerase IB, large subunit, putative | 0.0161 | 0 | 0.5 |
Toxoplasma gondii | DNA topoisomerase I, putative | 0.0215 | 0.323 | 0.5 |
Onchocerca volvulus | Serine\/threonine protein kinase homolog | 0.0328 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (ADMET) | = 62.8 uM | Cytotoxicity against human HeLa cells by SRB method | ChEMBL. | 24951333 |
MIC (functional) | = 55 ug ml-1 | Antimicrobial activity against Candida albicans NCIM-3471 after 20 hrs by two fold serial macrodilution technique | ChEMBL. | 24951333 |
MIC (functional) | = 80 ug ml-1 | Antimicrobial activity against Escherichia coli NCIM-2256 after 20 hrs by two fold serial macrodilution technique | ChEMBL. | 24951333 |
MIC (functional) | = 90 ug ml-1 | Antimicrobial activity against Cryptococcus neoformans NCIM-3378 after 20 hrs by two fold serial macrodilution technique | ChEMBL. | 24951333 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.